SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 148,711.01 |
| Enterprise Value ($M) | 212,738.01 |
| Book Value ($M) | 92,558.00 |
| Book Value / Share | 16.33 |
| Price / Book | 1.61 |
| NCAV ($M) | -74,541.00 |
| NCAV / Share | -13.15 |
| Price / NCAV | -2.00 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.05 |
| Return on Assets (ROA) | 0.04 |
| Return on Equity (ROE) | 0.08 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.92 |
| Current Ratio | 1.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 50,358.00 |
| Assets | 213,396.00 |
| Liabilities | 124,899.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 63,627.00 |
| Operating Income | 16,328.00 |
| Net Income | 8,031.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 12,744.00 |
| Cash from Investing | 2,652.00 |
| Cash from Financing | -17,140.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 8.97 | 0.97 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 8,801,874 | 48,219,947 | 18.25 | |
| 7,049,468 | 35,638,777 | 19.78 | |
| 5,184,954 | 30,250,360 | 17.14 | |
| 8,774,275 | 37,170,828 | 23.61 | |
| 9,251,093 | 43,937,593 | 21.06 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NUVB – Nuvation Bio Inc. | OGN – Organon & Co. |
| PBH – Prestige Consumer Healthcare Inc. | PRGO – Perrigo Company plc |
| QGEN – Qiagen N.V. |
Financial data and stock pages provided by
Fintel.io